Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab

Hematol Oncol. 2018 Oct;36(4):713-714. doi: 10.1002/hon.2533. Epub 2018 Aug 3.

Authors

Stefanie Aeppli¹, Christoph Driessen¹, Lukas Graf², Felicitas Hitz¹

Affiliations

¹ Department of Oncology/Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
² Center for Laboratory Medicine, Hemostasis and Hemophilia Center, St. Gallen, Switzerland.

PMID: 30074631
DOI: 10.1002/hon.2533

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Humans
Lymphoma, Extranodal NK-T-Cell / diagnostic imaging
Lymphoma, Extranodal NK-T-Cell / drug therapy*
Lymphoma, Extranodal NK-T-Cell / metabolism
Male
Meningeal Neoplasms / diagnostic imaging
Meningeal Neoplasms / drug therapy*
Meningeal Neoplasms / metabolism
Middle Aged
Recurrence

Substances

Antibodies, Monoclonal
daratumumab